Essential Thrombocythemia News and Research

RSS
Novartis receives EC approval for Jakavi to treat myelofibrosis

Novartis receives EC approval for Jakavi to treat myelofibrosis

Researchers uncover protein structure that regulates blood cell formation and activity

Researchers uncover protein structure that regulates blood cell formation and activity

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Incyte’s ruxolitinib COMFORT-II Phase III trial in MF meets primary endpoint

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte Corporation publishes clinical trial data of INCB18424 drug for myelofibrosis treatment

Incyte second-quarter total revenues increase to $49.8 million

Incyte second-quarter total revenues increase to $49.8 million

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Geron scientists highlight importance of telomerase inhibitor, GRN163L at AACR 2010

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte announces 2009 financial results and key fourth-quarter accomplishments

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

Incyte's INCB18424 provides previously unachievable clinical benefits in myelofibrosis patients

New treatment options for leukemia and myeloproliferative disorders introduced

New treatment options for leukemia and myeloproliferative disorders introduced

New data demonstrating the strength of Novartis' hematology portfolio to be presented

New data demonstrating the strength of Novartis' hematology portfolio to be presented

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

TargeGen completes JAK2 inhibitor TG101348 clinical trial in myelofibrosis patients

IND for Cytopia's CYT387 clears the FDA review

IND for Cytopia's CYT387 clears the FDA review

Experimental drug successfully blocks mutation in bone marrow cancers

Experimental drug successfully blocks mutation in bone marrow cancers

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

UIC receives $20 million NCI grant to research blood disorders

UIC receives $20 million NCI grant to research blood disorders